Dr. Juan Jose Andino, MD

Dr. Andino practices at County of Los Angeles Auditor Controller in Los Angeles, California.

Dr. Andino's NPI, 1053846584, was assigned on April 21, 2017. Dr. Andino graduated from University Of Michigan Medical School in 2017. Dr. Andino holds California license A177912.

Dr. Andino's primary practice is County of Los Angeles Auditor Controller, at 12021 Wilmington Ave, Los Angeles, CA 90059 in Los Angeles County. The practice phone is (310) 668-4501.

Dr. Andino's primary practice is County of Los Angeles Auditor Controller in Los Angeles, California. Dr. Andino is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is Martin Luther King Jr. Community Medical Group. Dmand AI also links Dr. Andino to 2 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Andino practices, 5 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Andino's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Andino is board certified in urology by the American Board of Urology. Dmand AI has Dr. Andino's licenses on file in 2 states: California and Michigan.

Dmand AI lists enlarged prostate, kidney removal surgery, kidney stone disease, testicular dysfunction and transurethral procedures among the conditions Dr. Andino treats.

CMS data shows 227 Medicare services from Dr. Andino across 7 procedure codes in 2024, for 152 Medicare patients. Medicare paid $18,971 for them. Every service was in an office.

CMS counts 152 Medicare patients who saw Dr. Andino in 2024. The largest group is 65 to 74, with 95 patients. 72% of them have high cholesterol, and 70% have high blood pressure. 35% are also on Medicaid. Their average risk score is 1.40, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Andino's median patient age at 48, with 3% women.

In 2024, Dr. Andino wrote 253 Medicare Part D claims for 81 patients. 92% of them were for generic drugs. CMS names the drug for 162 of them, across 8 drugs with 11 or more claims each, at $19,103 in total drug cost. In 2023, CMS named 176 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Andino for performance year 2024, reported through an alternative payment model (APM). Dr. Andino accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Andino as offering telehealth.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 7 papers to Dr. Andino, published from 2023 to 2025. 2025 was the busiest year, with 4. Dr. Andino's most frequent co-authors are Jesse N. Mills, MD, Brittany Deborah Berk, MD and Raevti Bole, MA, MD.

CMS Open Payments shows 123 general payments to Dr. Andino from 20 drug and device companies from 2021 to 2025. Grants make up the largest share, 84% of the total. Boston Scientific Corporation paid the most, $53,645.

Dr. Andino serves on SMSNA Technology & Communications and Society for Study of Male Reproduction.

Dr. Andino graduated from University Of Michigan Medical School in 2017. Dr. Andino is a member of AUA, California State Medical Society, Los Angeles County Medical Society, Sexual Medicine Society of North America, Society for the Study of Male Reproduction and Society of Prosthetic Urology Surgeons.

Dr. Andino is in network with 10 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.